Anti-androgen therapy, administered in the treatment of prostate cancer, implies the use of agonists of gonadotropin-releasing hormone (GnRH), like leuprolide and goserelin, beside oral anti-androgens, like flutamide and bicalutamide. Some recent trials have suggested the hypothesis that these drugs provoke an increase in cardiovascular risk and diabetes risk. With an observational trial, 37,000 patients treated for prostate cancer and belonging to the Veterans Administration, have been examined. About 40% of them have been treated with anti-androgens, and, after analyses adjusted for potential confounders, it was seen that monotherapy with GnRH agonists is associated with a statistically significant increased risk for the onset of type 2 diabetes (Hazard Ratio 1.28), myocardial infarction (HR 1.28) and stroke (1.21).
(Oncology)
Our comment:
August 2010
-

Fast speaking - File size: 1308 Kb Time 1,23 min.
-

Slow speaking - File size: 1446 Kb Time 1,32 min.
Breastfed children have the risk to develop rickets, so, in 2008, the American Academy of [...]
The American Committee for Vaccinations (U.S. Advisory Committee on Immunization Practices) has [...]
In a case-control trial, performed in Canada, the performance of colonoscopy has been associated [...]